PILA PHARMA’s clinical development candidate, XEN-D0501
PILA PHARMA’s clinical safe development candidate, XEN-D0501 was previously owned by Ario Pharma/ Xention and, before that, Bayer Healthcare that invented the molecule and took it through ‘first-in-man’.
The TRPV1 antagonist XEN-D0501 has previously been investigated in 6 clinical trials and has been found to be exceptionally well tolerated in man.
The TRPV1 target (also called the ‘chili-receptor’) has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes as well.
In addition to the development candidate, PILA PHARMA is the owner of use-patents giving the exclusive right to treat diabetes and obesity with TRPV1 antagonists (Read the use-patent application here)
A use-patent application on the use of XEN-D0501 as treatment of diabetes has been filed.